AU2019224850B2 — Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
Assigned to Glenmark Specialty SA · Expires 2024-11-28 · 1y expired
What this patent protects
The present invention relates to a method of treating allergic rhinitis in a pediatric subject in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its s…
USPTO Abstract
The present invention relates to a method of treating allergic rhinitis in a pediatric subject in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
Drugs covered by this patent
- Elocon (MOMETASONE FUROATE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.